[MUSIC] It is my pleasure to have
with us Sukhdeep Sahambi, and she is one of the scientists
at Novartis and Sukhdeep, I'm going to hand it straight to you to
allow you to introduce yourself please. >> Speaker 2: Thank you, Erland, thank you
for the opportunity to record this video. I am a preclinical safety
assessment expert in Nevada's institutes of
biomedical research. So, commonly what I do is known as PCSPTM. PCS stands for pre-clinical safety,
PTM stands for project team member. So, what I do is ensure that
pre-clinical safety assessment is done appropriately to support
the ongoing developmental phase of a compound that I am
supporting in that particular team. >> Speaker 1: Fantastic, could you tell us a little bit about
your educational background please? >> Speaker 2: Yes, I have a PhD,
I did a couple of postdocs, and I am a diplomat of American
board of toxicology. So, my schooling, all of my
schooling up till PhD is from India, I graduated in reproductive and developmental zoology from
Punjab Agricultural University. After that, I moved to Montreal and
I did two postdocs, both pursuing reproductive and developmental
toxicology and then I started working in pre-clinical contract research
companies, commonly known as CROs. And from there I came into Novartis, and it's been a wonderful
seven-year experience. >> Speaker 1: Fantastic, wonderful, what
are some typical activities that perhaps define general day or
week that you would have in your position? >> Speaker 2: A typical week
as a PCSPTM can broadly be divided into few buckets. Majority of the work is
done with a target team, which is a PCS specific
subject matter expert team. Then there is continuous
direction with the project team, which is a NIBR based team. Then there are trainings, there are some
non-scientific other activities including participating in workshops, running
workshops, and then some time to bring me up to speed on everything that's going on,
taking a step back about the target team. So, within PCS, we have for
every program that we support, and PCS supports all the programs within NIBR. And once they move into GDD, depending
on the level of support they need, PCS is involved on a very broad
level within the organization. So, target team is a group of
subject matter experts which are dedicated to making sure
that the safety assessment in the preclinical arena is being
conducted the right way. And so, this team includes a PTM,
an anatomic pathologist, a clinical pathologist,
a targeting toxicologist, an investigative sciences toxicologist,
and then we collaborate. We work very closely
with the pharmacokinetic sciences project team members, and so the target team works
very closely to design the experiments that we run to assess
the safety of a given compound. Designing the experiments,
executing them, reviewing the data, interpreting the data at different
stages of the experiments, different stages of the program,
that takes a big chunk of our time. And then depending on different
stages where the programs are, there could be very heavy
target team activity, there could be just some background
email communication that's ongoing. Second big part is interactions
with the project team, so as a project team member, the safety
representative on the project teams, my job is to understand and
contribute to the strategy. To ensure that the safety
assessment preclinically is being done the right way so
that we are developing the right clinical safety strategy to ensure
safe drugs into the clinic. And so, again,
depending on the phase of the program, it will involve different activities
including a lot of stakeholder management, one on one discussions,
smaller group meetings, larger group meetings,
presenting to different boards, and then a smaller portion of the time is
spent in trainings, workshops, reading. Sometimes there are some
findings that will require spending more time reading up,
okay, why do we have this finding? Is it on target, can we understand
if it's on target versus off target? What additional experiments do
we need to run within PCS or in collaboration with given disease area? What can we do to
understand this better and see whether this compound
can move forward or not? So, those are one of the most exciting
parts for me in preclinical safety is you don't know what's waiting for
you in your mailbox when you are logging [LAUGH] first thing in
the morning, there can be surprises. And those surprises most
of the times are exciting to resolve because it requires more work,
reading up, understanding, interaction
with some very smart people. So, lots of uncertainties that
we work with every single day, but that's what makes work a lot of fun. >> Speaker 1: That's great, can you talk
about some of what you would consider to be your essential skills in your position? >> Speaker 2: Being able
to communicate properly, ability to work with a variety
of people because within PCS, as I mentioned,
PCS supports all the programs within NIBR. So, we get to work with a variety of
scientists within different disease areas, but that also comes with
the challenge of having to work with different personalities and
different teams. Every team has different dynamics,
so you have to tailor your message to make sure that it's
being received the right way, being in preclinical safety,
one of the challenging parts of the job is to deliver the news
that your compound is very toxic. These findings will not be acceptable for
this patient population, we can't move this forward,
so that's part of the job. That news has to be delivered,
but different teams take the same message differently,
and also as the safety expert, many teams expect me to explain to them,
why did we see this? How else could we have designed this
experiment to get all the necessary information and also find a safe dose
that would help us move forward? So, making sure that I understand the team
dynamics, making sure that I am setting the expectations from the very beginning
and then meeting those expectations, understanding the science,
understanding the strategy, communication, those are some of
the skills that get me through every day. >> Speaker 1: It sounds like you provide
other people with surprises in their email inboxes as well. >> Speaker 2: [LAUGH] I do, I try to
talk to people rather than surprising everybody, if I can inform the PTLs,
it helps manage the message differently than somebody suddenly
finding out there's this challenge. And we currently don't see a way to
move forward, which to be honest, is the reason we do
preclinical safety assessment. We want to find all the liabilities
preclinically and then see whether, what's the translatability? Is this a challenge that we can
afford to have in the clinic? Is this finding really relevant to
the clinical population or not? So, lots of factors that need to
be considered, to be discussed and to be explained sometimes to the project
teams, okay, we have this finding, but this may really not be
translatable into the clinic. Or to the clinical population,
this really doesn't matter because this is an animal
species specific finding versus, we have this finding and I'm sorry,
we can't take this compound forward. Honestly, it really varies from team to
team for how they will take the message, I recently had a program where we had
some surprise findings in one species and not the other. So, now we have a question to answer,
is this just this species specific? What's the translatability? Why are we not seeing it
in the other species, and it has impacted the timelines, but
the team was very open in listening and understanding for
why we need to do additional work. The challenges sometimes there are just
target related challenges that you can't overcome no matter how
many different compounds you try. And so, I can see from the project
team members viewpoint, I have been working on this for
so long, and now you're coming in and
you're telling me this can't work. And we want to make sure that we have
exhausted all the avenues before we give up on a program. >> Speaker 1: At the same workshop they
did, and it was mostly organic chemists, people who had a chemistry background,
didn't know medicinal chemistry, but knew how to make molecules. And they said, you chemists like to
fall in love with your structures. >> [LAUGH] yes. >> because you know how to make them,
and the chemistry works, but when the biologist tells
you this is a dead series, you have to let it go and
find a series that does work. And so,
people do fall in love with certain, we lose sight of the big picture,
it happens. >> Speaker 2: Yes, yeah, I remember
in high school, there was a statement in the first chapter of the biology book,
biology is a science of exceptions. And so, I still remind myself that,
yeah, given the attrition rate in drug development,
I have to frequently remind myself, and I've been working on a program,
on a compound for some time, and then we get this data, and yes, I'm
delivering the news, but at the same time, I have to remind myself,
there's a reason we do these studies. And yeah, we might think we understand
biology, but we need to do a bit more, we need to understand a bit more,
if there's a difference in different aspects of this, just this given pathway,
so we need to understand more. And yeah,
it's all part of drug development, it's not an easy field, but it's fun. >> Speaker 1: Great, could you share anything about
your current work at Novartis? How your work engages you or
the benefit it will bring to patients? >> Speaker 2: Yes, so I am currently
involved in a few disease areas and programs supporting neuroscience and
ophthalmology, and in a couple of programs within DAX,
which we call a number of disease area x, which is broadly divided into benign
hematology, NASH and renal indications. So, quite a variety of programs which
provides insights into different strategies that we consider for
different patient populations, different safety findings that can be
tolerated for one patient population and those will not be acceptable for
other patient population. So, quite a variety that I am engaged in,
and, sorry, go ahead. >> Speaker 1: From CNS to the metabolic
disorders to, it's a range. >> Speaker 2: Yes. >> Speaker 1: So, what are some of
the challenges that you face in PCS and maybe hope that can be overcome someday? >> Speaker 2: [LAUGH] If I were
to pick one or to categorize, I think one of the biggest
challenges that we see or we face on a routine basis,
is the translatability between preclinical species and
into the clinic. For some targets, for some indications,
preclinical species that we use, provide very good scenario of
what could we see in the clinic. But there are challenges with certain
targets where we may not have the right animal model or there might be challenges
in selecting the right species to assess the appropriate safety markers
that we can then monitor in the clinic. So, within PCS, we routinely discuss how
do we overcome this, what are the tools? Can we look back at some
of the clinical and preclinical data in this indication and what type of translatability do we see and
what can we utilize from there? Variety of tools and
opportunities that we discuss to improve the translatability of preclinical
safety assessment into the clinic so that we are going with a very
robust plan into the clinic so the patients can benefit more. >> Speaker 1: Fantastic, Sukhdeep,
thank you so much for being available for this interview and
sharing your thoughts and experiences with
the participants in the course. >> Speaker 2: It is my pleasure,
thank you for the opportunity. >> Speaker 1: Great, thank you.